Results 31 to 40 of about 850,964 (168)

Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study

EClinicalMedicine, 2020
Background: Psilocybin therapy has shown promise as a rapid-acting treatment for depression, anxiety, and demoralization in patients with serious medical illness (e.g., cancer) when paired with individual psychotherapy. This study assessed the safety and
Brian T Anderson, Alicia Danforth, Prof Robert Daroff, Christopher Stauffer, Eve Ekman, Gabrielle Agin-Liebes, Alexander Trope, Matthew Tyler Boden, Prof James Dilley, Jennifer Mitchell, Joshua Woolley   +10 more
doaj   +1 more source

Therapeutic effect of psilocybin in addiction: A systematic review

Frontiers in Psychiatry, 2023
BackgroundPsychedelic-assisted therapy [e.g., with lysergic acid diethylamide (LSD)] has shown promising results as treatment for substance use disorders (SUDs).
Pim B. van der Meer, Pim B. van der Meer, Juan J. Fuentes, Juan J. Fuentes, Juan J. Fuentes, Ad A. Kaptein, Jan W. Schoones, Marleen M. de Waal, Marleen M. de Waal, Marleen M. de Waal, Anneke E. Goudriaan, Anneke E. Goudriaan, Anneke E. Goudriaan, Kees Kramers, Arnt Schellekens, Arnt Schellekens, Metten Somers, Matthijs G. Bossong, Albert Batalla   +18 more
doaj   +1 more source

Will psilocybin lose its magic in the clinical setting?

Therapeutic Advances in Psychopharmacology, 2022
Psilocybin as a novel treatment for depression is garnering a lot of attention from both the mainstream media and the academic community. Although phase 3 trials are only just beginning, we feel that it is important for clinicians to consider what ...
Caroline Hayes, Mourad Wahba, Stuart Watson   +2 more
doaj   +1 more source

The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions

Frontiers in Pharmacology, 2018
Research on the clinical applications of psychedelic-assisted psychotherapy has demonstrated promising early results for treatment of alcohol dependence.
Elizabeth M. Nielson, Darrick G. May, Alyssa A. Forcehimes, Michael P. Bogenschutz   +3 more
doaj   +1 more source

Psilocybin for Depression: From Credibility to Feasibility, What’s Missing?

Pharmaceuticals, 2022
Psilocybin has been suggested as a promising transdiagnostic treatment strategy for a wide range of psychiatric disorders. Recent findings showed that psychedelic-assisted/”psycholitic” psychotherapy should provide significant and sustained alleviation ...
Antonio Munafò, Davide Arillotta, Guido Mannaioni, Fabrizio Schifano, Renato Bernardini, Giuseppina Cantarella   +5 more
doaj   +1 more source

Therapeutic interventions for PTSD – current evidence on the the role of psychedelics

European Psychiatry, 2021
Introduction Post-traumatic stress disorder (PTSD) is often a chronic condition, despite the existence of evidence-based treatment options. Psychotherapy is the designated first line treatment for PTSD, although high rates of psychiatric and medical ...
I. Figueiredo, F. Viegas, F. Ferreira, A. Santos, J. Ramos, J. Miranda   +5 more
doaj   +1 more source

Psilocybin-Assisted Group Therapy and Attachment: Observed Reduction in Attachment Anxiety and Influences of Attachment Insecurity on the Psilocybin Experience [PDF]

, 2021
Attachment insecurity is determined early in life, is a risk factor for psychopathology, and can be measured on two separate continuous dimensions: attachment anxiety and attachment avoidance.
Stauffer, Christopher S, Ortigo, Kile M, Woolley, Joshua, Anderson, Brian T   +3 more
core   +1 more source

Study protocol of an open-label proof-of-concept trial examining the safety and clinical efficacy of psilocybin-assisted therapy for veterans with PTSD

BMJ Open, 2023
Introduction Psilocybin-assisted therapy has shown significant promise in treating the cluster of mood and anxiety symptoms that comprise post-traumatic stress disorder (PTSD) but has yet to be tested specifically in this condition.
Alan K Davis, Adam W Levin, Paul B Nagib, Stacey B Armstrong, Rafaelle L Lancelotta   +4 more
doaj   +1 more source

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences

Scientific Reports, 2023
Psilocybin and lysergic acid diethylamide (LSD) experiences can range from very positive to highly challenging (e.g., fear, grief, and paranoia). These challenging experiences contribute to hesitancy toward psychedelic-assisted psychotherapy among health
Richard J. Zeifman, Hannes Kettner, Broc A. Pagni, Austin Mallard, Daniel E. Roberts, David Erritzoe, Stephen Ross, Robin L. Carhart-Harris   +7 more
doaj   +1 more source

Oregon psilocybin services. American Sign Language

, 2022
This video is in American Sign Language (ASL) and translates a 2-page fact sheet on the topic of Oregon Psilocybin Services.This archived document is maintained by the State Library of Oregon as part of the Oregon Documents Depository Program.

core